Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 6/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL18130856 | 1.00 | PTGER2 (0.44) | PTGER2PTGER3PTGER4HTTTLR4 | |
| Acetic Acid SCHEMBL4134829 | 1.00 | PTGER2 (0.44) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL158776 | 0.92 | CYP1A2 (0.43) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL8964738 | 0.92 | CYP1A2 (0.43) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL8965184 | 0.92 | CYP1A2 (0.43) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL8964734 | 0.92 | CYP1A2 (0.43) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL8965187 | 0.92 | CYP1A2 (0.43) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL8600712 | 0.90 | CYP1A2 (0.46) | PTGER2PTGER3PTGER4HTTTSHR | |
| Acetic Acid Methyl Ester SCHEMBL28101633 | 0.89 | HTT (0.45) | PTGER2PTGER3PTGER4HTTTLR4 | |
| SCHEMBL1614409 | 0.86 | HTT (0.40) | PTGER2PTGER3PTGER4HTTTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045479-B2 | Treatments for resistant acne | VYOME THERAPEUTICS LIMITED (IN) | 2021-06-29 | — | — | US | disclosed |
| EP-3698793-A1 | BESIFLOXACIN FOR THE TREATMENT OF RESISTANT ACNE | Vyome Therapeutics Limited (IN) | 2020-08-26 | — | — | EP | disclosed |
| US-20180318313-A1 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2018-11-08 | — | — | US | disclosed |
| US-10071103-B2 | Treatments for resistant acne | VYOME BIOSCIENNCES PVT. LTD. (IN) | 2018-09-11 | — | — | US | disclosed |
| EP-2300146-B1 | PROCESS FOR PREPARING POLYUREA MICROCAPSULES | FIRMENICH & CIE (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20160346294-A1 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2016-12-01 | — | — | US | disclosed |
| US-20160128944-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME THERAPEUTICS LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20150164117-A1 | ENCAPSULATION OF FRAGRANCE AND/OR FLAVORS IN SILK FIBROIN BIOMATERIALS | TUFTS UNIVERSITY | 2015-06-18 | — | — | US | disclosed |
| US-20140023688-A1 | ENCAPSULATED OILS | FIRMENICH SA (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8426353-B2 | Process for preparing polyurea microcapsules | FIRMENICH SA (CH) | 2013-04-23 | — | — | US | disclosed |
| US-20110077188-A1 | PROCESS FOR PREPARING POLYUREA MICROCAPSULES | FIRMENICH SA | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071103-B2 | Treatments for resistant acne | RARB, CUTA, RARG | PTGER2 1072/4885PTGER3 821/4885PTGER4 1131/4885 |
| US-20150164117-A1 | ENCAPSULATION OF FRAGRANCE AND/OR FLAVORS IN SILK FIBROIN BIOMATERIALS | OR51E2, TRPA1, TAS2R20 | PTGER2 1184/4885PTGER3 1906/4885PTGER4 1161/4885 |
| US-20180318313-A1 | TREATMENTS FOR RESISTANT ACNE | RARB, CUTA, RARG | PTGER2 1072/4885PTGER3 821/4885PTGER4 1131/4885 |
| US-20160346294-A1 | TREATMENTS FOR RESISTANT ACNE | CUTA, RARB, RARG | PTGER2 1014/4885PTGER3 855/4885PTGER4 1277/4885 |
| US-11045479-B2 | Treatments for resistant acne | RARB, CUTA, RARG | PTGER2 1072/4885PTGER3 821/4885PTGER4 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.